These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 35057893)
21. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells. Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700 [TBL] [Abstract][Full Text] [Related]
22. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472 [TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. Gao J; Dai C; Yu X; Yin XB; Zhou F J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108 [TBL] [Abstract][Full Text] [Related]
24. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24. Hu Z; Zhao Y; Mang Y; Zhu J; Yu L; Li L; Ran J Life Sci; 2023 Jul; 325():121773. PubMed ID: 37187452 [TBL] [Abstract][Full Text] [Related]
25. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741 [No Abstract] [Full Text] [Related]
26. cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence. Ruan Y; Chen T; Zheng L; Cai J; Zhao H; Wang Y; Tao L; Xu J; Ji L; Cai X Int J Biol Sci; 2023; 19(14):4608-4626. PubMed ID: 37781045 [TBL] [Abstract][Full Text] [Related]
27. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Azumi J; Tsubota T; Sakabe T; Shiota G Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977 [TBL] [Abstract][Full Text] [Related]
28. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1. Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319 [TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB. Fang L; Sun J; Pan Z; Song Y; Zhong L; Zhang Y; Liu Y; Zheng X; Huang P Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G150-G156. PubMed ID: 28526689 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Long J; Jiang C; Liu B; Fang S; Kuang M Tumour Biol; 2016 May; 37(5):5821-8. PubMed ID: 26581909 [TBL] [Abstract][Full Text] [Related]
32. Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line. Zhao G; Han C; Zhang Z; Wang L; Xu J Biochem Biophys Res Commun; 2017 Aug; 490(2):371-377. PubMed ID: 28623129 [TBL] [Abstract][Full Text] [Related]
33. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737. Zhao G; Wang T; Huang QK; Pu M; Sun W; Zhang ZC; Ling R; Tao KS World J Gastroenterol; 2016 Jun; 22(23):5364-73. PubMed ID: 27340352 [TBL] [Abstract][Full Text] [Related]
35. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268 [TBL] [Abstract][Full Text] [Related]
36. Long Non-Coding RNA NEAT1 Promoted Hepatocellular Carcinoma Cell Proliferation and Reduced Apoptosis Through the Regulation of Let-7b-IGF-1R Axis. Liu Q; Shi H; Yang J; Jiang N Onco Targets Ther; 2019; 12():10401-10413. PubMed ID: 31819522 [TBL] [Abstract][Full Text] [Related]
37. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC. Xu J; Wang Y; Zhang Y; Dang S; He S Biomed Pharmacother; 2018 Nov; 107():1682-1691. PubMed ID: 30257386 [TBL] [Abstract][Full Text] [Related]
38. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326 [TBL] [Abstract][Full Text] [Related]
39. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271 [No Abstract] [Full Text] [Related]
40. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. de la Cruz-Ojeda P; Schmid T; Boix L; Moreno M; Sapena V; Praena-Fernández JM; Castell FJ; Falcón-Pérez JM; Reig M; Brüne B; Gómez-Bravo MA; Giráldez Á; Bruix J; Ferrer MT; Muntané J Cells; 2022 Aug; 11(17):. PubMed ID: 36078082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]